6月26日，艾伯维公司盘中上涨3.31%，报251.23美元/股，成交额22.61亿美元。消息面上，公司近日宣布以约109亿美元全现金收购Apogee Therapeutics，获取核心资产zumilokibart，UBS认为该交易估值"充分合理"，该药在特应性皮炎及哮喘领域具备"超级重磅炸弹潜力"。同时，Canaccord Genuity将目标价上调至273美元，Rothschild & Co Redburn上调至284美元，均维持买入评级。产品端，Skyrizi获欧盟批准扩展至儿童银屑病，Maviret获批用于急性丙肝，多重利好共振持续推升股价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.